Med. praxi. 2019;16(3):148-152 | DOI: 10.36290/med.2019.053

Neuropathic pain treatment

MUDr. Marek Hakl, Ph.D.
Klinika algeziologie a preventivní péče, Medicinecare, s.r.o., Brno
Chirurgická klinika FN Brno a LF MU

Neuropathic pain is one of the most difficult pain condition to treat. Many common analgesics are ineffective in treating it. In therapy to the forefront are coming above all mainly a group of drugs from anticonvulsants, anti depressives, opioids with increased affinity to neuropathic pain and lately new topical form of medicaments. Occurrence of the neuropathic pain is increasing exponentially with the age of the patients, and at the same time the tolerance of the patients to anti neuropathic treatment is decreasing. Major benefit to treatment of the neuropathic pain was formation of unified EFNS guidelines on which the national guidelines are based. The most common form of the neuropathic pain are polyneuropathy, trigeminal neuralgia, postherpetic neuralgia or central neurogenic pain.

Keywords: neuropathic pain, anticonvulsants, opioids, guidelines

Received: August 12, 2019; Accepted: September 6, 2019; Prepublished online: September 6, 2019; Published: June 28, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hakl M. Neuropathic pain treatment. Med. praxi. 2019;16(3):148-152. doi: 10.36290/med.2019.053.
Download citation

References

  1. Bouhassira D, Lanteri-Minet M, Attal N, Laureát B, Touboul C. Prevalence of chronic pain with neuropathic characteristic in the general population. Pain 2008; 136: 380-387. Go to original source... Go to PubMed...
  2. Atta N, Cruccu G, Baron R, Haanpaa M, Hanson P, Jensen T, Numikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. European Journal of Neurology 2009; 8: 1010-1018. Go to original source...
  3. Attal N, Cruccu G, Haanpiiii M, et al. EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathicpain. EurJ Neurol 2006; 13: 1153-1169. Go to original source... Go to PubMed...
  4. Bednařík J, Amber Z, Opavský J, et al. Klinický standard pro farmakoterapii neuropatické bolesti. Cesk Slov Neurol 2012; 75/108(1): 93-101.
  5. Ambler Z. Neuropatická bolest. In Bolest. Rokyta R. Bolest. Praga: Tigis 2006: 227-244.
  6. Backonja M, Glanzman RL. Gabapentin Dosing for Neuropathic Pain: Evidence from Randomized, Placebo-Controlled Clinical Trials. Clinical Therapeutics, 2003; 25(1): 81-104. Go to original source... Go to PubMed...
  7. Nicholson B. Gabapentin use in neuropathic pain syndromes, Acta Neurol Scand 2000; 101: 359-371. Go to original source... Go to PubMed...
  8. Ambler Z. Pregabalin v léčbě neuropatické bolesti. Farmakoterapie 2011; 7(Suppl.1): 49-52.
  9. Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Family Practice 2010; 11: 85-97. Go to original source... Go to PubMed...
  10. Lejčko J, Kozák J. Metodické pokyny pro léčbu chronické nenádorové bolesti. Bolest 2016; suppl 1: 19-21.
  11. Hakl M. Léčba neuropatické bolesti. Neurologie pro praxi 2016; 17(2): 113-116. Go to original source...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.